# EDGAR Filing Document

**Accession Number:** 0001707502
**File Stem:** 0000899243-23-003084
**Filing Date:** 2023-1
**Character Count:** 7627
**Document Hash:** 3864dc47408685ebd91e2959e3eef745
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-003084.hdr.sgml**: 20230131

**ACCESSION NUMBER**: 0000899243-23-003084

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230127

**FILED AS OF DATE**: 20230131

**DATE AS OF CHANGE**: 20230131

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ganot Ilan
- **CENTRAL INDEX KEY:** 0001727460

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38360
- **FILM NUMBER:** 23574526

**MAIL ADDRESS:**
- **STREET 1:** C/O SOLID BIOSCIENCES, LLC
- **STREET 2:** 141 PORTLAND STREET, FIFTH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Solid Biosciences Inc.
- **CENTRAL INDEX KEY:** 0001707502
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 900943402
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 500 RUTHERFORD AVENUE
- **STREET 2:** 3RD FLOOR
- **CITY:** CHARLESTOWN
- **STATE:** MA
- **ZIP:** 02129
- **BUSINESS PHONE:** 617-337-4680

**MAIL ADDRESS:**
- **STREET 1:** 500 RUTHERFORD AVENUE
- **STREET 2:** 3RD FLOOR
- **CITY:** CHARLESTOWN
- **STATE:** MA
- **ZIP:** 02129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Solid Biosciences, LLC
- **DATE OF NAME CHANGE:** 20170524

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ganot Ilan<br><sub>(Last) (First) (Middle)</sub><br>C/O SOLID BIOSCIENCES INC.<br>500 RUTHERFORD AVENUE, THIRD FLOOR<br><sub>(Street)</sub><br>CHARLESTOWN, MA 02129<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-27 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Solid Biosciences Inc. [ SLDB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-27 |  | M |  | 388 | A | <sup>(1)</sup> | 1519<sup>(2)</sup> | I | Wife |
| Common Stock | 2023-01-27 |  | S |  | 141<sup>(3)</sup> | D | $7.49 | 1378 | I | Wife |
| Common Stock | 2023-01-27 |  | M |  | 3883 | A | <sup>(1)</sup> | 85973<sup>(4)</sup> | D |  |
| Common Stock | 2023-01-27 |  | S |  | 1382<sup>(3)</sup> | D | $7.49 | 84591 | D<sup>(5)</sup> |  |
| Common Stock |  |  |  |  |  |  |  | 19394 | I | See Footnote<sup>(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | 2023-01-27 |  | M |  |  | 388 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 388 | $0.00 | 1165 | I | Wife |
| Restricted Stock Units | <sup>(1)</sup> | 2023-01-27 |  | M |  |  | 3883 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 3883 | $0.00 | 11650 | D |  |

---

### Footnotes:

(1) Restricted stock units convert into common stock on a one-for-one basis.

(2) Includes 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2022.

(3) This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

(4) Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively.

(5) Represents 81,931 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

(6) Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

(7) On January 27, 2022 (the "Grant Date"), Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

(8) On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

**Signature:** /s/ by David Tyrone Howton as attorney-in-fact for Ilan Ganot  
**Date:** 2023-01-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**